CAM
AARD

Cresset Asset Management’s Aardvark Therapeutics AARD Stock Holding History

Cresset Asset Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Sell
24,033
-19,226
-44% -$89.8K ﹤0.01% 1637
2026
Q1 		$163K Buy
+43,259
New +$448K ﹤0.01% 1503
2025
Q4 		– Sell
-141,783
Closed -$1.88M – 1713
2025
Q3 		$1.88M Buy
+141,783
New +$1.6M 0.01% 553

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Cresset Asset Management's AARD Position: Q2 2026 in Review

Cresset Asset Management reduced its Aardvark Therapeutics (AARD) stake by 44% in Q2 2026, selling an estimated $89.8K and leaving 24,033 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Cresset Asset Management first reported a position in AARD in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.88M in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Cresset Asset Management held 24,033 shares of Aardvark Therapeutics worth $138K as of Q2 2026.
  • Cresset Asset Management sold 19,226 Aardvark Therapeutics shares in Q2 2026, an estimated $89.8K.
  • Aardvark Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1637 holding.
  • Cresset Asset Management first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Cresset Asset Management's Aardvark Therapeutics position peaked at $1.88M in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.